Skip to main content

News of Note—Johnson & Johnson, Bavarian Nordic and more

newspaper
In this week's news of note, Johnson & Johnson announced a data publication for its "mosaic-based" HIV vaccine. (Pixabay)

Here is some other vaccine news of note for the week:

> Johnson & Johnson announced that The Lancet published data from its phase 1/2b study of a "mosaic-based" HIV vaccine. The company advanced the shot to an efficacy test last November. Release | FiercePharma article

> Bavarian Nordic announced that a phase 2 trial of the company's cancer vaccine CV301 and Bristol-Myers Squibb's Opdivo started in patients with resectable hepatic-limited metastatic colorectal cancer. Release

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

> MabVax licensed an antibody development program for multiple cancers to Boehringer Ingelheim for $11 million upfront, plus undisclosed milestones. Release

> Even though Neovacs' therapeutic lupus vaccine missed a primary efficacy endpoint in a phase 2b study, the company is moving into phase 3 based on other results. Release

> Altimmune named Mitchel Sayare, Ph.D., its executive chairman and José Ochoa its chief business officer. Release